Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313508 | 0.82 | PLAT (0.42) | PLATNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10275482 | 0.81 | PLAT (0.40) | PLATNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10276231 | 0.80 | CNR1 (0.41) | PLATNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10275316 | 0.78 | KIF11 (0.43) | PLATNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10276122 | 0.75 | PLAT (0.40) | PLATNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10275442 | 0.74 | ARF6 (0.41) | PLATNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL13516176 | 0.73 | MAPT (0.41) | MAPTALDH1A1CYP11B2KDM4E | |
| SCHEMBL10313475 | 0.72 | ALPL (0.41) | PLATALDH1A1CNR1 | |
| SCHEMBL10275518 | 0.72 | PDE2A (0.37) | NPC1MAPTRAB9APDE2ASLC22A12 | |
| SCHEMBL13515966 | 0.70 | MAPT (0.46) | PLATNPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | PLAT 2180/4885NPC1 1381/4885MAPT 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.